

Our pathway to net zero impact on climate

We're committed to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

This document gives more detail on the pathway we have set to a net zero impact on climate, although there are many interdependencies with our [nature goals](#).

Our climate targets

We have set a clear pathway to a net zero impact on climate. By 2030, we aim to reduce carbon emissions by 80% with the remainder covered through investment in high-quality nature-based solutions, and by 2045, we aim to be at the Science Based Target Initiative Net Zero Standard, with carbon emissions reduced by at least 90% and the remainder tackled through high-quality carbon credits.

2025

100% imported renewable electricity by 2025 and 100% renewable electricity (imported and generated) by 2030 (Scope 2)

2030

80% absolute reduction in greenhouse gas emissions from a 2020 baseline, across all scopes and investment in nature-based solutions for the remaining 20% of our footprint by 2030

2045

Net zero greenhouse gas emissions across our full value chain by 2045: 90% absolute reduction in emissions from a 2020 baseline, across all scopes and all residual emissions neutralised

- Our net zero targets cover the full value chain of emissions reductions, from a baseline of 2020.
- Our net zero targets have been approved by the Science Based Target Initiative’s Corporate Net-Zero Standard, the world’s only framework for corporate net-zero target setting in line with climate science.¹
- We disclose progress against these targets annually in our Annual Report and Responsible Business Performance Report.


¹ You can find our approved targets on the SBTi website [here](#)

Our value chain carbon footprint

We have mapped our carbon footprint across our value chain to ensure we have a clear understanding of where to focus our efforts, which informs our pathway to net zero.

Supply chain


Scope 3 emissions from the goods and services that GSK buys from other companies and other upstream emissions.



| | |
|---------------------|--|
| Purchased goods | 1.90m tonnes CO ₂ e per annum |
| Purchased services | 1.08m tonnes CO ₂ e per annum |
| Capital investments | 0.23m tonnes CO ₂ e per annum |
| Commuting | 0.06m tonnes CO ₂ e per annum |
| Business travel | 0.23m tonnes CO ₂ e per annum |
| Upstream energy | 0.07m tonnes CO ₂ e per annum |

GSK’s operations

Scope 1 and 2 emissions from running our labs, factories and commercial offices.*




| | |
|---------------------------------|--|
| Energy | 0.37m tonnes CO ₂ e per annum |
| HFA and manufacturing emissions | 0.23m tonnes CO ₂ e per annum |
| Sales force | 0.05m tonnes CO ₂ e per annum |

* Scope 1 and 2 market-based emissions

Logistics


Scope 3 emissions from delivering medicines and vaccines across the globe.



| | |
|----------------------|--|
| Upstream logistics | 0.21m tonnes CO ₂ e per annum |
| Downstream logistics | 0.08m tonnes CO ₂ e per annum |

Patient use


Scope 3 emissions from patients using our products.



| | |
|------------------------------|--|
| Use of metered dose inhalers | 5.04m tonnes CO ₂ e per annum |
| Use of other products | 0.04m tonnes CO ₂ e per annum |

Disposal

Scope 3 emissions from the disposal of our products by GSK patients.



9.63m

Total estimated GSK emissions

tonnes CO₂e per annum*


* based on data from 2023

Priority actions to reduce emissons

We are taking action to reduce emissions across our full value chain, prioritising the highest impact areas.

Purchased goods and services


Scope 3 emissons



- Sustainable Procurement Programme, driving targeted supplier engagement and setting sustainability standards
- Deep engagement with 30 most impactful suppliers
- Peer collaboration through Sustainable Markets Initiative (SMI) and Energize programme to decarbonise our shared supply chains
- Manufacture 2030 helping with engagement, measurement and the development of emission reduction glidepaths for suppliers
- Activate programme with peers to reduce the environmental impact in Active Pharmaceutical Ingredient value chains
- Converge, a collaborative supply chain initiative by My Green Lab, to encourage suppliers to reduce the environmental impact of labs in the value chain

GSK’s operations


Scopes 1 and 2 emissons



- Renewable electricity and heat**
- Members of RE100
 - Onsite production through wind turbines and solar panels, together with buying renewable electricity and through power purchase agreements
 - Starting to generate heat through renewable electricity or biofuels
- Electric vehicles**
- Members of EV100
 - Committed to transition our fleet to low-carbon vehicles by 2030
 - Target to install charging infrastructure at 100 sites
- Energy reductions**
- Ongoing focus on energy efficiency programmes

Logistics


Scope 3 emissons



- Maximising transition from air freight to sea freight
- Using AI to optimise route options

Patient use


Scope 3 emissons



- Predominantly from the propellant used in metered dose inhalers (MDIs) for asthma and chronic obstructive pulmonary disease
- Investing in a low-carbon programme and if successful, it has the potential to reduce greenhouse gas emissions from the inhaler by 90% by transitioning to a next generation, lower-carbon propellant. Phase III trials began in 2024 and, if successful, regulatory submissions will start in 2025
- Beyond MDIs, product stewardship programme to embed eco-design principles for all new products

Disposal

Scope 3 emissons



- Founding member of the Circularity in Primary Pharmaceutical Packaging Accelerator, an initiative across the pharmaceutical supply chain to develop and deploy solutions for the recycling of primary pharmaceutical packaging

Our approach to carbon credits

Whilst we are focused on emissions reductions to meet our carbon targets, at the same time, we are investing in high quality nature protection and restoration projects that support our net-zero and nature positive goals, and deliver co-benefits to human health.

We plan to secure carbon credits for the 20% emissions we estimate to have as residual in 2030, and for a maximum of 10% residual emissions by 2045 (from a 2020 baseline). We aim to secure all of the credits for the 2030 target through nature investments by 2028 and we report our progress annually in the Responsible Business Performance Report. These credits will be issued later in the decade and will be retired against our 2030 residual emissions and onwards, yearly.

For our 2030 target we are prioritizing carbon removal credits, but we will also secure a proportion of carbon avoidance and reductions credits in recognition of their critical role in conserving existing carbon stocks and protecting nature. For our 2045 Net Zero target, we will aim to only secure carbon removal credits.

We plan to secure carbon credits for the 20% emissions we estimate to have as residual in 2030, and for a maximum of 10% residual emissions by 2045.

Credit quality and integrity

We understand the scepticism around the quality of some of the existing carbon credits in the Voluntary Carbon Market (VCM). We aim to invest in high quality and high integrity projects:

- We partner with expert developers and NGOs to invest in early-stage projects for the long term and ensure the design is inclusive of nature and health co-benefits.
- We work with external experts to identify appropriate criteria for investments, covering carbon technical aspects (scientific verification, additionality, leakage, permanence etc) and other impacts (avoidance of harm, benefit-sharing mechanism, IPLC and vulnerable communities' co-benefits, scientific innovation, etc).
- We work with multiple partners to run extensive due diligence on projects before investments.
- We continue to review evolving and emerging guidance documents, including those provided by the Voluntary Carbon Market Initiative and Science Based Targets Initiative, to ensure we are aligned with leading experts guiding the use of carbon credits.
- In partnership with Pollination, and with input from key nature and health experts from organisations such as the Circular Bioeconomy Alliance, the Nature Climate Solutions Alliance and the London School of Hygiene and Tropical Medicine we have published an [open-source toolkit](#) to support companies, investors and developers to incorporate health considerations in the design of nature-based projects.
- We are open to co-investment opportunities if they increase the scale of the potential impact on the ground and reduce the risks, intrinsic in nature projects.

Current projects in our portfolio

GSK is an investor in Climate Asset Management's Nature Based Carbon Fund, which aims to invest at a landscape scale in grassland, agriculture, forestry, wetlands and coastal carbon projects in developing economies, to provide long-lasting, verified, positive impact at scale for the climate, biodiversity and local communities.

In 2024, we invested in a peat and mangrove protection and restoration project in Indonesia. Rewetting, reforestation, monitoring, and fire prevention measures will enable emission reductions and long-term carbon storage, as well as biodiversity protection.

The project includes specific interventions such as training, supporting sustainable economic activities, and a Healthy Village Program, which involves initiatives such as providing capacity building to the community healthcare workers and health education for the local communities concerning sanitation, nutrition and newborn care.


We are part of the LEAF coalition (Lowering Emissions by Accelerating Forest finance), a private-public effort to protect tropical forests.

We recognise that this is a fast-moving space, and that methodologies and guidelines will likely evolve as we implement our plans.

We commit to remaining flexible and transparent about our progress and learning.

Our pathway to net zero

The graph below shows our projected carbon reduction pathway to 2030 and 2045 across the different parts of our carbon footprint, along with our planned carbon credits.





Ahead Together

More information

- [Our position on Access and Benefit Sharing](#)
- [Our position on Pharmaceuticals in the Environment](#)
- [Our position on Antimicrobial Resistance](#)
- [Our plan for contributing to a nature positive world](#)
- [Reducing the environmental impact of our medicines and vaccines](#)